EMA
- Application: EMEA/H/C/004230
- Local brand name: Mavenclad
- Status: approved
Leustatin (CLADRIBINE) regulatory status in European Union.
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. EMA has authorised it.
Marketing authorisation holder not available in our data.